SCHEMBL31348947

SCHEMBL31348947

CCCCCCCCc1ccccc1/C=C\CCCCCCCCCC(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.48
CYSLTR2 Q9NS75 2/20 0.47
CYSLTR1 Q9Y271 2/20 0.47
F7 P08709 3/20 0.46
F3 P13726 3/20 0.46
MMP2 P08253 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
ECE1 P42892 1/20 0.46
SGMS1 Q86VZ5 1/20 0.46
SGMS2 Q8NHU3 1/20 0.46
MUS81 Q96NY9 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SAE1 Q9UBE0 1/20 0.46
SOAT2 O75908 1/20 0.46
SOAT1 P35610 1/20 0.46
FAAH O00519 1/20 0.44
PPARG P37231 1/20 0.44
ALOX5 P09917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25713055 1.00 EPHX2 (0.48) EPHX2CYSLTR2CYSLTR1F7F3
SCHEMBL25713054 1.00 EPHX2 (0.48) EPHX2CYSLTR2CYSLTR1F7F3
SCHEMBL10519228 0.96 PPARG (0.47) EPHX2CYSLTR2CYSLTR1F7F3
SCHEMBL9801991 0.96 PPARG (0.47) EPHX2CYSLTR2CYSLTR1F7F3
SCHEMBL10746693 0.93 CYSLTR2 (0.48) EPHX2CYSLTR2CYSLTR1F7F3
SCHEMBL10746705 0.93 CYSLTR2 (0.48) EPHX2CYSLTR2CYSLTR1F7F3
SCHEMBL10794770 0.87 PPARG (0.52) EPHX2CYSLTR2CYSLTR1SOAT2SOAT1
SCHEMBL10794771 0.87 PPARG (0.52) EPHX2CYSLTR2CYSLTR1SOAT2SOAT1
SCHEMBL30462675 0.86 SOAT1 (0.55) EPHX2CYSLTR2CYSLTR1F7F3
SCHEMBL31047993 0.86 SOAT1 (0.55) EPHX2CYSLTR2CYSLTR1F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250019341-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) 2025-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250019341-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES TLR3, CGAS, NOD2 EPHX2 3792/4885CYSLTR2 1382/4885CYSLTR1 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.